Eli Lilly threatens 340B hospital discounts over data compliance

Eli Lilly has issued an ultimatum to more than 1,000 hospitals enrolled in the 340B drug discount program: submit claims data within five days or lose access to discounted pricing. The move escalates a years-long standoff between pharmaceutical manufacturers and safety-net hospitals over data transparency in the federal program.

The 340B program requires drugmakers to provide discounts—often 25% to 50% off list price—to hospitals serving low-income and uninsured patients. Manufacturers have increasingly demanded detailed claims-level data to verify that discounts are not being duplicated when patients also have commercial or Medicaid coverage. Hospitals argue these requests exceed statutory requirements and expose proprietary patient information.

Lilly's five-day deadline represents one of the more aggressive enforcement tactics yet deployed by a manufacturer. The company has not publicly disclosed which specific data fields it is requesting or how it will verify compliance. Other major manufacturers including AstraZeneca and Sanofi have implemented similar data-sharing conditions over the past two years, but typically with longer ramp periods.

The hospital lobby has consistently opposed these unilateral data mandates, and multiple federal court rulings have sided with manufacturers' ability to impose conditions on 340B pricing beyond the program's statutory minimum. The Health Resources and Services Administration, which oversees 340B, has issued guidance discouraging manufacturer restrictions but lacks clear enforcement authority to halt them.

If Lilly follows through and cuts off discounts to non-compliant hospitals, affected institutions will face a choice: pay full wholesale acquisition cost for Lilly drugs, switch to competing therapies where available, or submit the data under protest. For hospitals with tight margins, even a temporary loss of 340B pricing on high-cost drugs can translate to seven-figure monthly impacts.